KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone
June 26 2017 - 3:05PM
US Patent and Trademark Office issues patent
protection to KP746, an investigational therapy for the treatment
of pain with a prodrug of oxymorphone
KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs, today announced a further enhancement
to KemPharm's U.S. and global intellectual property
estate governing its portfolio of prodrug product candidates with
the addition of a patent for KP746, a prodrug of oxymorphone.
“This first patent for KP746 continues to build our strong
patent estate of intellectual property that underpins our entire
prodrug product portfolio,” said Travis Mickle, Ph.D., KemPharm
President and Chief Executive Officer. "We believe that KP746 could
be designated a New Molecular Entity, or NME, by the FDA. As
a prodrug of oxymorphone, it is currently in preclinical
development for the potential treatment of moderate to severe acute
and chronic pain. All of our growing patent estate is predicated on
allowing us ample time to commercially develop our products,
offering the potential of both an immediate and a sustained
protected value proposition.”
KemPharm was recently issued U.S. Patent No. 9,682,076 from the
United States Patent and Trademark Office (USPTO) for its patent
application entitled “Benzoic acid, benzoic acid derivatives and
heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs,
methods of making and use thereof.” The patent, which extends
through 2035, provides compositions of matter for treating moderate
to severe pain, specifically comprising a compound and compositions
of oxymorphone conjugated to 6-diflunisal.
About KemPharm
KemPharm is a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through
its LATTM (Ligand Activated Therapy) platform technology.
KemPharm utilizes its LATTM platform technology to generate
improved prodrug versions of U.S. Food and Drug Administration
(FDA)-approved drugs in the high need areas of pain, attention
deficit hyperactivity disorder (ADHD) and other central nervous
system (CNS) disorders. KemPharm’s co-lead clinical development
candidates are KP415, an extended-release (ER) prodrug of
methylphenidate for the treatment of ADHD, and KP201/IR, an
acetaminophen-free formulation of the company’s immediate release
(IR) abuse deterrent hydrocodone product candidate, KP201.
For more information on KemPharm and its pipeline of prodrug
product candidates visit www.kempharm.com.
Caution Concerning Forward Looking
StatementsThis press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts, and can be identified
by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. These forward-looking statements include
statements regarding the expected features and characteristics of
KP746 and the anticipated scope of KemPharm’s intellectual property
rights based on development of its patent portfolio. These
forward-looking statements are not guarantees of future actions or
performance. These forward-looking statements are based on
information currently available to KemPharm and its current plans
or expectations, and are subject to a number of uncertainties and
risks that could significantly affect current plans. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
KemPharm's financial resources and whether they will be sufficient
to meet KemPharm's business objectives and operational
requirements; results of earlier studies and trials may not be
predictive of future clinical trial results; the protection and
market exclusivity provided by KemPharm's intellectual property;
risks related to the drug discovery and the regulatory approval
process; the impact of competitive products and technological
changes; obligations to third parties regarding the potential
commercialization or sale of KP201/IR, KP415 or KP746; and the FDA
approval process, including without limitation any timelines for
related approval. KemPharm's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its
results to differ materially from those expressed or implied by
such forward-looking statements. These and other risks concerning
KemPharm’s business are described in additional detail in
KemPharm's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017, and KemPharm’s other Periodic and Current Reports
filed with the Securities and Exchange Commission. KemPharm
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com
Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.
202-329-1825
dcohen@kempharm.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2024 to May 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From May 2023 to May 2024